BiotechTV - News

Raymond James Biotech Innovation Symposium: Korro Bio CEO Ram Aiyer discussed how the company has chosen new RNA editing programs to move forward with this year

Raymond James Biotech Innovation Symposium: Dyne's CEO John Cox shares an overview of the company's recent landmark DMD data

Raymond James Biotech Innovation Summit: Checking in with Vera's Founder & CEO Marshall Fordyce ahead of the July 7 FDA decision date for the APRIL & BAFF targeting IgAN treatment Atacicept

Raymond James Biotech Innovation Symposium: Akebia's CEO John Butler shares an update on the launch of Vafseo and discusses two of the company's pipeline programs

Raymond James Biotech Innovation Symposium: Wave Life Sciences CEO Paul Bolno discusses the recent INHBE data and previews alpha-1 antitrypsin deficiency data being presented next month

Raymond James Biotech Innovation Symposium: Tectonic Therapeutic develops biologics against GPCR targets - and is making headway on an unmet need for pulmonary hypertension in heart failure patients

Raymond James Biotech Innovation Symposium: Eupraxia has a novel extended release platform for - with data already out and more on the way later this year, Eosinophilic Esophagitis has been a good PoC

Raymond James Biotech Innovation Symposium: Septerna is developing oral small molecules that target GPCRs, it now has two programs in the clinic

Raymond James Biotech Innovation Symposium: Raymond James analyst Chris Raymond shares his take on biotech and companies he covers

Harbinger Health is announcing its emphasis on a new category of cancer screening tests today, RESOLVE, that are meant to be used upon the suspicion of cancer symptoms to speed diagnosis and treatment

Spyre Therapeutics announced today that SPY001, an extended half-life α4β7, showed a 40% clinical remission rate at 12 weeks in moderate-to-severe UC

Alloy Therapeutics announced a deal with Biogen today to help them discover antisense therapeutics using Alloy's ASO platform. Alloy Founder & CEO Errik Anderson fills us in at the company's R&D Day.

The new CEO of Stoke Therapeutics, Ian Smith, discusses Stoke Therapeutics' Dravet syndrome therapy, which caught much attention after publishing phase 1/2 data in NEJM last month

Iambic's CEO Tom Miller discusses the company's approach to AI drug discovery (hint: it's way more than protein folding), and highlights the company's clinical HER2 program, and two others on the way

Already this year Chai Discovery has raised a $130M series B and struck a discovery partnership with Eli Lilly - Co-Founder Jack Dent describes how Chai is using AI to design antibodies

CellCentric has kicked off dosing of its first registration-supporting study for the oral p300/CBP inhibitor inobrodib in multiple myeloma today

Coya Therapeutics' CEO Arun Swaminathan discusses the company's focus on harnessing T-regs to treat neurodegenerative diseases

RBC Biotech Analyst Leo Timashev shares his take on the sector and discusses companies he covers that are in the news

Solid Biosciences CEO Bo Cumo discusses recent DMD data for the company's microdystrophin gene therapy, and explains the development and regulatory steps ahead

Solid Biosciences' CEO, Bo Cumbo, discusses the company's gene therapy advancements for Duchenne muscular dystrophy, emphasizing their focus on improved delivery methods via the Polaris capsid. Cumbo highlights recent data from a Phase 1-2 study involving 41 patients, noting the comprehensive safety profile and consist...

Christian Tidona's BioMed X and Michal Preminger are launching BioMed X Venture Labs in Cambridge, MA to create 'build to solve' startups with partners